Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Hemalatha G. Rangarajan(Nationwide Children's Hospital), Jeffery J. Auletta(Nationwide Children's Hospital), Olle Ringdén(Karolinska Institutet), Erin Doherty(QB3), Marcie Riches(Medical College of Wisconsin), Nosha Farhadfar(University of Florida Health), Hemant S. Murthy(University of Florida), Emily M. Hsieh(Children's Hospital of Los Angeles), Vanessa A. Fabrizio(Children's Hospital Colorado), Zeinab El Boghdadly(The Ohio State University Wexner Medical Center), Lena E. Winestone(University of California, San Francisco), Shahrukh K. Hashmi(Mayo Clinic), Prakash Satwani(Pediatrics and Genetics), Nasheed Hossain(Loyola University Chicago), Kitsada Wudhikarn, Matthew S. Kelly, Samuel John(Southwestern Medical Center), Amar H. Kelkar(Harvard University), Christopher E. Dandoy(Cincinnati Children's Hospital Medical Center), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Brian D. Friend(The University of Texas MD Anderson Cancer Center), Megan M. Herr(Roswell Park Comprehensive Cancer Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Anna R. Huppler(Medical College of Wisconsin), Dipenkumar Modi(Wayne State University), Min Chen(Jianghan University), Hongtao Liu(University of Chicago), Michael J. Martens(Medical College of Wisconsin), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Tim Prestidge(Starship Children's Health)
Cited by 5
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880